Cantargia treats first triple-negative breast cancer patient in randomized phase II part of TRIFOUR trial
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that, following positive results in the lead-in phase of the clinical phase Ib/II trial TRIFOUR, the first triple-negative breast cancer (TNBC) patient has initiated treatment with the IL1RAP-binding antibody nadunolimab (CAN04) and chemotherapy in the phase II randomized part of the trial. Up to 98 patients may be included in this part and the next milestone, an interim futility analysis of 28 patients, is estimated in Q4 2023.“We are proud to have started Cantargia’s first randomized trial with nadunolimab, in patients with